PegBio Co

PegBio Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PegBio Co (2565.HK) as of Nov 19, 2026 is -205.91 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -280.85 M CNY — a change of -26.69% (higher).

EBITDA

-205.91 MCNY

YoY

-26.69%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PegBio Co is 2025 -205.91 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PegBio Co was 2024 -280.85 M CNY. It decreases by -26.69% higher compared to the previous year.

The PegBio Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-318.47 M CNY
Jan 1, 2023
-277.45 M CNY
Jan 1, 2024
-280.85 M CNY
Jan 1, 2025
-205.91 M CNY
The PegBio Co EBITDA history
YEAREBITDAYoY
-205.91 MCNY-26.69%
-280.85 MCNY+1.22%
-277.45 MCNY-12.88%
-318.47 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PegBio Co is -205.91 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PegBio Co changed from -280.85 M CNY to -205.91 M CNY, representing a -26.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PegBio Co

All Key Metrics — PegBio Co